Statistical issues in the analysis of adverse events in time-to-event data

Pharmaceutical Statistics

Volumn 15, Issue 4, 2016, Pages 297-305

  Allignol, Arthur ^a   Beyersmann, Jan ^a   Schmoor, Claudia ^b  

^a UNIVERSITY OF ULM   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

Author keywords

Aalen Johansen; competing risks; safety; survival

Indexed keywords

AALEN JOHANSEN ESTIMATOR; ADVERSE DRUG REACTION; CONFERENCE PAPER; DEATH; HAZARD; INCIDENCE; KAPLAN MEIER METHOD; NONPARAMETRIC TEST; PROBABILITY; PROPORTIONAL HAZARDS MODEL; STATISTICAL ANALYSIS; SURVIVAL ANALYSIS; TIME TO EVENT DATA;

EID: 84978832833     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1739     Document Type: Conference Paper

References (28)

1. ICH Expert Working Group. ICH Harmonised Tripartite Guideline. Statistical principles for clinical trials E9, 1995. Available at: http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E9/Step4/E9_Guideline.pdf (accessed 27.8.2015).
2. O'Neill RT. Statistical analyses of adverse event data from clinical trials special emphasis on serious events. Drug Information Journal 1987; 21(1):9–20.
3. Gait JE, Smith S, Brown SL. Evaluation of safety data from controlled clinical trials: the clinical principles explained. Drug Information Journal 2000; 34(1):273–287.
4. Moore K, van der Laan M. Application of time-to-event methods in the assessment of safety in clinical trials. Design and Analysis of Clinical Trials with Time-to-Event Endpoints. Taylor & Francis, Chapman & Hall/CRC, Boca Raton, 2009; 455–482.
5. Nishikawa M, Tango T, Ogawa M. Non-parametric inference of adverse events under informative censoring. Statistics in Medicine 2006; 25(23):3981–4003.
6. Wang J, Quartey G. Nonparametric estimation for cumulative duration of adverse events. Biometrical Journal 2012; 54(1):61–74.
7. Gong Q, Tong B, Strasak A, Fang L. Analysis of safety data in clinical trials using a recurrent event approach. Pharmaceutical Statistics 2014; 13(2):136–144.
8. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Statistics in Medicine 1999; 18(6):695–706.
9. Beyersmann J, Allignol A, Schumacher M. Competing Risks and Multistate Models with r. Springer: New York, 2011.
10. Beyersmann J, Scheike TH. Classical Regression Models for Competing Risks, Handbook of Survival Analysis. CRC Press: Boca Raton, 2013.
11. Beyersmann J, Gastmeier P, Schumacher M. Incidence in ICU populations: how to measure and report it? Intensive Care Medicine 2014; 40:871–876.
12. Grambauer N, Schumacher M, Dettenkofer M, Beyersmann J. Incidence densities in a competing events analysis. American Journal of Epidemiology 2010; 172(9):1077–1084.
13. Kraemer HC. Events per person-time (incidence rate): a misleading statistic? Statistics in Medicine 2009; 28(6):1028–1039.
14. Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. Journal of the American Statistical Association 1999; 94(446):496–509.
15. Schmoor C, Schumacher M, Finke J, Beyersmann J. Competing risks and multistate models. Clinical Cancer Research 2013; 12:12–21.
16. Andersen PK, Keiding N. Interpretability and importance of functionals in competing risks and multistate models. Statistics in Medicine 2012; 31(11-12):1074–1088.
17. Kleinbaum DG, Klein M. Survival Analysis (3rd edn). Springer: New York, 2012.
18. Aalen OO, Borgan Ø, Gjessing HK. Survival and Event History Analysis, Statistics for Biology and Health. Springer-Verlag: New York, 2008.
19. Andersen PK, Borgan Ø, Gill RD, Keiding N. Statistical Models Based on Counting Processes. Springer-Verlag: New-York, 1993.
20. Tai BC, Wee J, Machin D. Analysis and design of randomised clinical trials involving competing risks endpoints. Trials 2011; 12(1):127–137.
21. Rauch G, Beyersmann J. Planning and evaluating clinical trials with composite time-to-first-event endpoints in a competing risk framework. Statistics in Medicine 2013; 32(21):3595–3608.
22. Windeler J, Lange S. Events per person year – a dubious concept. British Medical Journal 1995; 310(6977):454–456.
23. Vandenbroucke J. Continuing controversies over ‘risks and rates’ – more than a century after William Farr's ‘on prognosis’. Soz.— Präventivmed 2003; 48:216–218.
24. Cook RJ, Lawless JF. The Statistical Analysis of Recurrent Events. Springer: New York, 2007.
25. Zinßer T, Schumacher M. Modeling time-dependency in analysis of adverse events by the example of the CLEOPATRA study, 2015. submitted to Pharmaceutical Statistics.
26. ICH Expert Working Group. ICH Harmonised Tripartite Guideline: Structure and Content of Clinical Study Reports E3, 1995. Available at: http://www.ich.org/fileadmin/Public_{W}eb_{S}ite/ICH_{P}roducts/Guidelines/Efficacy/ E3/E3_{G}uideline.pdf (accessed 27.8.2015).
27. Council for International Organizations of Medical Sciences – CIOMS Working Group VI. Management of Safety Information from Clinical Trials. CIOMS: Geneva, 2005.
28. Latouche A, Allignol A, Beyersmann J, Labopin M, Fine JP. A competing risks analysis should report results on all cause-specific hazards and cumulative incidence functions. Journal of Clinical Epidemiology 2013; 66(6):648–653.